$2.41
-0.01 (-0.41%)
USD · as of 2026-08-19 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where LXRX is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
61 interventional · 32 with posted results
Held by 11 tracked-famous managers (Point72 Asset Management, L.P., CITADEL ADVISORS LLC, MILLENNIUM MANAGEMENT LLC, RENAISSANCE TECHNOLOGIES LLC, SUSQUEHANNA INTERNATIONAL GROUP, LLP, +6 more) · FINRA short interest 12.5 days to cover (settled 2026-07-31) · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Updated |
|---|---|---|---|---|---|---|---|
| A Study to Evaluate the Efficacy and Safety of Sotagliflozin in Symptomatic Obstructive and Non-obstructive Hypertrophic CardiomyopathyNCT06481891Change from Baseline to Week 26 in Kansas City Cardiomyopathy Questionnaire Clinical Summary Score (KCCQ CSS)Randomized · Quadruple-masked · Treatment | Phase 3 | Active, not recruiting | Drug: Sotagliflozin, Placebo | Obstructive Cardiomyopathy, Hypertrophic, Non-obstructive Hypertrophic Cardiomyopathy | 500 | Jul 2026 | 2026-07-29 |
| A Dose-ranging Study in Patients With Diabetic Peripheral Neuropathic Pain (DPNP)NCT06203002Change from Baseline to Week 8 in Average Daily Pain Score (ADPS)Randomized · Quadruple-masked · Treatment | Phase 2 | Completed | Drug: Placebo (blinded), LX9211 (blinded) | Diabetic Peripheral Neuropathic Pain | 496 | 2025-01-14actual | 2025-10-10 |
| Efficacy and Safety of LX9211 in Participants With Postherpetic NeuralgiaNCT04662281results2026-02-13Change From Baseline (Week 2 of the Run-in Period) in Average Daily Pain Score (ADPS)Randomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: Placebo, LX9211 | Postherpetic Neuralgia | 79 | 2022-11-18actual | 2026-02-13 |
| Efficacy, Safety, and PK of LX9211 in Participants With Diabetic Peripheral Neuropathic PainNCT04455633results2025-06-25Change From Baseline to Week 6 in ADPS as Measured by the Numerical Rating ScaleRandomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: LX9211, LX9211 Matching Placebo | Diabetic Peripheral Neuropathy, Diabetes | 319 | 2022-05-23actual | 2025-06-25 |
| Effect of Sotagliflozin on Cardiovascular and Renal Events in Participants With Type 2 Diabetes and Moderate Renal Impairment Who Are at Cardiovascular RiskNCT03315143results2022-10-28Number of Total Occurrences of Cardiovascular (CV) Death, Hospitalizations for Heart Failure (HHF) and Urgent Visits for Heart Failure (HF)Randomized · Quadruple-masked · PreventionStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Terminatedsponsor's stated reason: study terminated due to business decision | Drug: Sotagliflozin, Placebo | Heart Failure, Type 2 Diabetes Mellitus, Chronic Kidney Diseases | 10,584 | 2020-07-08actual | 2022-10-28 |
| Effect of Sotagliflozin on Cardiovascular Events in Participants With Type 2 Diabetes Post Worsening Heart Failure (SOLOIST-WHF Trial)NCT03521934results2022-10-28Number of Total Occurrences of Cardiovascular (CV) Death, Hospitalizations for Heart Failure (HHF) and Urgent Visits for Heart Failure (HF)Randomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Terminatedsponsor's stated reason: Study terminated due to business decision | Drug: Sotagliflozin, Placebo | Heart Failure, Type 2 Diabetes Mellitus | 1,222 | 2020-06-05actual | 2022-10-28 |
| Efficacy and Safety of Sotagliflozin Versus Placebo in Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control While Taking Insulin Alone or With Other Oral Antidiabetic AgentsNCT03285594results2021-05-11Change From Baseline in Hemoglobin A1c (HbA1c) at Week 18Randomized · Double-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: Sotagliflozin, Insulin glargine (HOE901), Placebo, Oral Antidiabetes Drugs (OADs) | Type 2 Diabetes Mellitus | 571 | 2019-09-17actual | 2021-05-11 |
| Safety, Tolerability and Pharmacodynamic Activity of Sotagliflozin in Hemodynamically Stable Participants With Worsening Heart FailureNCT03292653results2021-05-11Percentage of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs), AEs of Special Interest (AESIs), AEs Leading to Discontinuation From the Investigational Medicinal Product (IMP) and DeathsRandomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Terminatedsponsor's stated reason: 1st two cohorts provided the required data, therefore 3rd cohort was not deemed necessary | Drug: Sotagliflozin, Placebo | Cardiac Failure Aggravated | 32 | 2019-08-17actual | 2021-05-11 |
| Efficacy and Safety of Sotagliflozin Versus Glimepiride and Placebo in Participants With Type 2 Diabetes Mellitus That Are Taking Metformin MonotherapyNCT03332771results2021-05-11Change From Baseline in Hemoglobin A1c at Week 52Randomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: Sotagliflozin (SAR439954), Glimepiride, Metformin, Placebo, Placebo | Type 2 Diabetes Mellitus | 954 | 2019-08-06actual | 2021-05-11 |
| Efficacy and Bone Safety of Sotagliflozin 400 and 200 mg Versus Placebo in Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic ControlNCT03386344results2021-06-25Change From Baseline in Hemoglobin A1c (HbA1c) at Week 26Randomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Terminatedsponsor's stated reason: Study terminated prematurely for financial reasons and Covid-19 pandemic. | Drug: Sotagliflozin, Placebo | Type 2 Diabetes Mellitus | 376 | 2019-05-22actual | 2021-06-25 |
| A Study to Evaluate Safety and Effects of Sotagliflozin 400 and 200 mg on Glucose Control in Participants With Type 2 Diabetes, Severe Impairment of Kidney Function and Inadequate Blood Sugar ControlNCT03242018results2021-06-25Change From Baseline in HbA1c at Week 26 Comparing Sotagliflozin 400 mg Versus PlaceboRandomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: Placebo, Sotagliflozin | Type 2 Diabetes Mellitus, Chronic Kidney Disease Stage 4 | 277 | 2019-05-16actual | 2021-06-25 |
| Efficacy and Safety of Sotagliflozin Versus Placebo and Empagliflozin in Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control While Taking a DPP4 Inhibitor Alone or With MetforminNCT03351478results2021-05-11Change From Baseline in Hemoglobin A1c (HbA1c) % at Week 26Randomized · Double-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: Sotagliflozin, Empagliflozin, Placebo, Placebo | Type 2 Diabetes Mellitus | 770 | 2019-05-16actual | 2021-05-11 |
| Efficacy and Safety of Sotagliflozin Versus Placebo in Patients With Type 2 Diabetes Mellitus Not Currently Treated With Antidiabetic TherapyNCT02926937results2021-06-21Change From Baseline in Hemoglobin A1c (HbA1c) at Week 26 (Sotagliflozin 400 mg Versus Placebo)Randomized · Double-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: Sotagliflozin (SAR439954), Placebo | Type 2 Diabetes Mellitus | 399 | 2019-04-22actual | 2021-06-21 |
| Efficacy and Safety of Sotagliflozin Versus Placebo in Participants With Type 2 Diabetes Mellitus on Background of Sulfonylurea Alone or With MetforminNCT03066830results2021-05-11Change From Baseline in Hemoglobin A1c (HbA1c) at Week 26Randomized · Double-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: Sotagliflozin (SAR439954), Placebo, Metformin, Sulfonylurea | Type 2 Diabetes Mellitus | 507 | 2019-04-17actual | 2021-05-11 |
| Safety and Efficacy Study of Sotagliflozin on Glucose Control in Participants With Type 2 Diabetes, Moderate Impairment of Kidney Function, and Inadequate Blood Sugar ControlNCT03242252results2021-06-25Change From Baseline in HbA1c at Week 26Randomized · Triple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: Placebo, Sotagliflozin | Type 2 Diabetes Mellitus, Chronic Kidney Disease Stage 3 | 787 | 2019-03-25actual | 2021-06-25 |
| Efficacy and Safety of Sotagliflozin Versus Placebo in Patients With Type 2 Diabetes Mellitus on Background of MetforminNCT02926950results2021-05-11Change From Baseline in Hemoglobin A1c (HbA1c) at Week 26Randomized · Double-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: Sotagliflozin (SAR439954), Placebo, Metformin | Type 2 Diabetes Mellitus | 518 | 2019-02-26actual | 2021-05-11 |
| Telotristat Etiprate - Expanded Treatment for Patients With Carcinoid Syndrome SymptomsNCT02026063results2019-09-17Number of Participants With Treatment-Emergent Adverse Events (TEAEs)Non-randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: Telotristat etiprate | Carcinoid Syndrome | 124 | 2018-09-12actual | 2019-09-17 |
| Study to Evaluate the Pharmacokinetics of Telotristat Ethyl in Subjects With Severe Hepatic ImpairmentNCT03423446Maximum observed concentration of telotristat ethylNon-randomized · Open-label · Treatment | Phase 1 | Completed | Drug: Telotristat Ethyl | Hepatic Impairment | 16 | 2018-06-15actual | 2018-10-15 |
| A Phase 1 Study to Evaluate the Effects of Omeprazole and Famotidine on the Absorption of Telotristat Ethyl in Healthy SubjectsNCT03302845Maximum observed concentration of telotristat ethylRandomized · Open-label · Basic science | Phase 1 | Completed | Drug: Omeprazole 40 MG, Famotidine 40 mg, Telotristat ethyl 250 mg | Drug-drug Interaction | 32 | 2017-10-23actual | 2018-04-25 |
| Study to Evaluate Sotagliflozin in Subjects With Varying Degrees of Renal FunctionNCT02647918Number of treatment emergent adverse eventsNon-randomized · Open-label · Treatment | Phase 1 | Completed | Drug: Sotagliflozin, Sotagliflozin | Renal Impairment, Healthy | 50 | Sep 2017actual | 2019-02-26 |
| A Phase 3 Study to Evaluate the Safety of Sotagliflozin in Patients With Type 1 Diabetes Who Have Inadequate Glycemic Control With Insulin Therapy AloneNCT02531035results2019-11-19Percentage of Participants With A1C <7.0% at Week 24 and No Episode of Severe Hypoglycemia and No Episode of Diabetic Ketoacidosis (DKA) After RandomizationRandomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: Sotagliflozin, Placebo | Type 1 Diabetes Mellitus (T1DM), High Level of Sugar (Glucose) in the Blood | 1,405 | Apr 2017actual | 2020-02-12 |
| Efficacy, Safety, and Tolerability Study of Sotagliflozin as Adjunct Therapy in Adult Patients With Type 1 Diabetes Mellitus Who Have Inadequate Glycemic Control With Insulin TherapyNCT02421510results2019-10-30Change From Baseline in A1C at Week 24Randomized · Quadruple-masked · Treatment | Phase 3 | Completed | Drug: Sotagliflozin, Sotagliflozin, Placebo | Type 1 Diabetes Mellitus | 782 | Nov 2016actual | 2020-02-12 |
| Efficacy and Safety of Sotagliflozin in Young Adult Patients With Type 1 Diabetes Mellitus and Elevated Hemoglobin A1CNCT02383940results2019-10-30Change From Baseline in Hemoglobin A1C (A1C) at Week 12Randomized · Triple-masked · Treatment | Phase 2 | Completed | Drug: Sotagliflozin, Placebo | Type 1 Diabetes Mellitus | 87 | Sep 2016actual | 2020-02-12 |
| Efficacy, Safety, and Tolerability Study of Sotagliflozin as Adjunct Therapy in Adult Patients With Type 1 Diabetes Mellitus Who Have Inadequate Glycemic Control With Insulin TherapyNCT02384941results2019-11-25Change From Baseline in A1C at Week 24Randomized · Triple-masked · Treatment | Phase 3 | Completed | Drug: Placebo, Sotagliflozin | Type 1 Diabetes Mellitus | 793 | Sep 2016actual | 2020-02-12 |
| Dose-ranging Study in Patients With Type 1 Diabetes MellitusNCT02459899results2019-10-30Change From Baseline in Hemoglobin A1C (A1C) at Week 12Randomized · Quadruple-masked · Treatment | Phase 2 | Completed | Drug: Placebo, Sotagliflozin | Type 1 Diabetes Mellitus | 141 | Aug 2016actual | 2020-02-12 |
| Telotristat Etiprate for Carcinoid Syndrome TherapyNCT02063659results2017-09-25Number of Participants With Treatment-Emergent Adverse Events (TEAEs) in the Double-Blind Treatment PeriodRandomized · Triple-masked · Treatment | Phase 3 | Completed | Drug: Telotristat etiprate, Placebo | Carcinoid Syndrome | 76 | 2016-03-29actual | 2018-02-26 |
| TELESTAR (Telotristat Etiprate for Somatostatin Analogue Not Adequately Controlled Carcinoid Syndrome)NCT01677910results2017-09-18Change From Baseline in the Number of Bowel Movements (BMs) Per Day Averaged Over 12 WeeksRandomized · Quadruple-masked · Treatment | Phase 3 | Completed | Drug: Telotristat etiprate, Placebo-matching telotristat etiprate | Carcinoid Syndrome | 135 | 2016-03-21actual | 2018-02-27 |
| PK Study of Sotagliflozin in Subjects With Hepatic ImpairmentNCT02471274Plasma concentration of sotaglifozin to evaluate protocol specified PK parametersNon-randomized · Open-label · Treatment | Phase 1 | Completed | Drug: sotagliflozin | Hepatic Impairment, Healthy | 32 | Dec 2015actual | 2016-11-17 |
| Oral Contraceptive DDI StudyNCT02494609Plasma concentration of sotaglifozin to evaluate protocol specified PK parametersNon-randomized · Open-label · Treatment | Phase 1 | Unknown status | Drug: sotagliflozin, oral contraceptive, oral contraceptive + sotagliflozin | Healthy | 30 | Nov 2015actual | 2016-03-02 |
| Bioequivalence Study Between 400 mg LX4211 Tablets and 2 X 200 mg LX4211 TabletsNCT02373046AUCRandomized · Open-label · Treatment | Phase 1 | Completed | Drug: LX4211, LX4211 | Healthy | 30 | Apr 2015actual | 2015-10-02 |
| DDI Study With Multiple-dose LX4211 and Single Dose DigoxinNCT02300350AUCNon-randomized · Open-label · Treatment | Phase 1 | Completed | Drug: Treatment A digoxin, Treatment B LX4211, Treatment C Digoxin + 400 mg LX4211 administered concomitantly | Healthy | 24 | Dec 2014actual | 2015-07-09 |
| DDI Study With Multiple-dose LX4211 and Single Dose RosuvastatinNCT02300363AUCNon-randomized · Open-label · Treatment | Phase 1 | Completed | Drug: Treatment A (rosuvastatin), Treatment B (LX4211), Treatment C (rosuvastatin + 400 mg LX4211 administered concomitantly) | Healthy | 24 | Nov 2014actual | 2015-07-09 |
| Phase 1, Open-label, Drug-drug Interaction Study With Octreotide Acetate Injection and Telotristat Etiprate in Healthy SubjectsNCT02195635Plasma concentrations of telotristat ethylNon-randomized · Open-label · Treatment | Phase 1 | Completed | Drug: Telotristat etiprate, Octreotide acetate | Drug Interactions | 24 | Oct 2014actual | 2016-09-07 |
| A Open-Label Drug-Drug Interaction Study of Telotristat Etiprate and Midazolam in Healthy SubjectsNCT02147808Midazolam plasma concentration in combination with steady state telotristat etiprateOpen-label · Treatment | Phase 1 | Completed | Drug: Telotristat etiprate, Midazolam | Drug Interactions | 24 | Aug 2014actual | 2014-09-08 |
| A Thorough QT Study of Telotristat EtiprateNCT02155205Mean change from baseline QT interval corrected for heart rateRandomized · Triple-masked · Treatment | Phase 1 | Completed | Drug: Telotristat etiprate, Placebo, Moxifloxacin | QT Interval | 48 | Aug 2014actual | 2014-09-08 |
| An Open-Label Drug-Drug Interaction Study of Telotristat Etiprate and Fexofenadine in Healthy SubjectsNCT02157558Fexofenadine plasma concentration in combination with steady state telotristat etiprateOpen-label · Treatment | Phase 1 | Completed | Drug: Fexofenadine, Telotristat etiprate | Drug Interactions | 24 | Aug 2014actual | 2014-09-08 |
| An Open-Label Food Effect Study of Telotristat EtiprateNCT02157584Plasma concentrations of telotristat ethylRandomized · Open-label · Treatment | Phase 1 | Completed | Drug: Telotristat etiprate, Telotristat etiprate | Healthy | 22 | Jul 2014actual | 2014-09-08 |
| Study of Telotristat Etiprate (LX1606) in Participants With Symptomatic Carcinoid Syndrome Not Managed by Stable-Dose Octreotide TherapyNCT00853047results2018-12-26Number of Participants With Any Treatment-emergent Adverse Event (TEAE) and Any Drug-related TEAE in the Core PhaseRandomized · Triple-masked · Treatment | Phase 2 | Completed | Drug: Telotristat etiprate, Octreotide LAR Depot, Placebo | Carcinoid Syndrome | 23 | Jun 2014actual | 2018-12-26 |
| Study of Telotristat Etiprate (LX1606) in Participants With Symptomatic Carcinoid SyndromeNCT01104415results2018-04-06Number of Participants With Any Treatment Emergent Adverse Events (TEAEs) and Drug-Related TEAEs in the Core PhaseRandomized · Open-label · Treatment | Phase 2 | Completed | Drug: Telotristat etiprate | Carcinoid Syndrome | 15 | 2014-02-12actual | 2019-03-15 |
| Safety and Efficacy of Sotagliflozin (LX4211) in Patients With Inadequately Controlled Type 1 Diabetes MellitusNCT01742208results2019-10-30Percent Change From Baseline in Total Daily Bolus Amount of Exogenous Insulin Required Calculated Over Days 3 to 27 (Treatment Outpatient Period)Randomized · Quadruple-masked · Treatment | Phase 2 | Completed | Drug: Sotagliflozin, Placebo, Sotagliflozin | Type 1 Diabetes Mellitus | 36 | Jan 2014actual | 2020-02-12 |
| Study to Define the Electrocardiogram Effects of a Single Dose of LX4211 in Healthy SubjectsNCT01913002Change from baseline in QTc intervalsRandomized · Quadruple-masked · Treatment | Phase 1 | Completed | Drug: LX4211 800 mg, LX4211 2000 mg, moxifloxacin 400 mg, LX4211 Placebo | Healthy | 63 | Oct 2013actual | 2013-10-30 |
| Study to Determine the Safety, Tolerability and Pharmacokinetics Following Multiple Doses of LX4211 in Healthy SubjectsNCT01916850Number of Participants with Adverse EventsRandomized · Quadruple-masked · Treatment | Phase 1 | Completed | Drug: LX4211 400 mg, LX4211 800 mg, LX4211 Placebo | Healthy | 25 | Oct 2013actual | 2013-10-30 |
| Study to Evaluate the Effect of Single Doses of LX4211 and Canagliflozin on Intestinal Glucose Absorption in Healthy Adult SubjectsNCT01916863Change from baseline in rate of glucose appearance after meal (RaO)Randomized · Quadruple-masked · Treatment | Phase 1 | Completed | Drug: LX4211 400 mg, canagliflozin 300 mg, LX4211 Placebo | Healthy Subjects | 25 | Oct 2013actual | 2013-10-30 |
| A Multi-Center Trial to Determine the Safety and Efficacy of LX1033 in Subjects With Diarrhea-Predominant Irritable Bowel SyndromeNCT01494233Change from baseline in stool consistencyRandomized · Quadruple-masked · Treatment | Phase 2 | Completed | Drug: 250 mg LX1033 tablets, Placebo tablet | Irritable Bowel Syndrome | 373 | Sep 2013actual | 2015-03-23 |
| An Open-label Study to Evaluate the Absorption, Metabolism, and Excretion of [14C]-Telotristat Etiprate in MalesNCT01932528Maximum plasma concentration of LX1606 and LX1033Open-label · Treatment | Phase 1 | Completed | Drug: 500 mg [14C]-LX1606 | Carcinoid Syndrome | 8 | Sep 2013actual | 2013-10-23 |
| A Study to Evaluate Safety and Efficacy of Telotristat Etiprate (LX1606) in Participants With Acute, Mild to Moderate Ulcerative ColitisNCT01456052results2015-03-11Number of Participants Experiencing a Treatment Emergent Adverse EventRandomized · Quadruple-masked · Treatment | Phase 2 | Completed | Drug: Telotristat Etiprate, Placebo | Ulcerative Colitis | 59 | 2013-09-03actual | 2019-05-23 |
| Study to Evaluate the Pharmacodynamic and Pharmacokinetic Effects of LX4211 in Subjects With Type 2 Diabetes and Renal ImpairmentNCT01555008Change from baseline in postprandial glucoseRandomized · Quadruple-masked · Treatment | Phase 1 | Completed | Drug: LX4211, LX4211 Placebo | Type 2 Diabetes Mellitus, Renal Impairment | 31 | Aug 2013actual | 2013-09-09 |
| Study to Determine the Absorption, Metabolism, and Excretion of [14C]LX4211 in Healthy Male SubjectsNCT01818232Area Under Curve (AUC)Open-label · Treatment | Phase 1 | Completed | Drug: [14C]-LX4211 | Healthy | 8 | May 2013actual | 2013-06-18 |
| A Study to Determine the Safety and Efficacy of LX3305 in Subjects With Active Rheumatoid ArthritisNCT01417052Number of subjects experiencing an adverse event (AE)Randomized · Quadruple-masked · Treatment | Phase 1 | Completed | Drug: 50 mg LX3305 QD, 100 mg LX3305 QD, 150 mg LX3305 QD, 200 mg LX3305 QD, 250 mg LX3305 QD, 300 mg LX3305 QD, 400 mg LX3305 QD, 250 mg LX3305 BID, 500 mg LX3305 QD, Placebo | Rheumatoid Arthritis | 10 | Jun 2012actual | 2012-08-02 |
| Study to Evaluate the Safety, Tolerability, and Efficacy of LX7101 in Subjects With Primary Open-angle Glaucoma or Ocular HypertensionNCT01528111Number of subjects experiencing an adverse eventRandomized · Quadruple-masked · Treatment | Phase 1/2 | Completed | Drug: LX7101 (0.125%), LX7101 (0.25%), LX7101 Vehicle | Primary Open-angle Glaucoma, Ocular Hypertension | 63 | Jun 2012actual | 2015-09-14 |
| Safety and Efficacy of LX4211 With Metformin in Type 2 Diabetes Patients With Inadequate Glycemic Control on MetforminNCT01376557results2014-10-31Change From Baseline in HbA1c to Week 12Randomized · Quadruple-masked · Treatment | Phase 2 | Completed | Drug: 75 mg LX4211, 200 mg LX4211, 400 mg LX4211, 200 mg LX4211, Placebo | Type 2 Diabetes Mellitus | 299 | May 2012actual | 2014-10-31 |
| A Study to Evaluate the Pharmacodynamic Effects of Single-Dose Co-Administration of LX4211 With Januvia® in Type 2 DiabeticsNCT01441232Change from baseline in gut hormonesRandomized · Open-label · Treatment | Phase 1 | Completed | Drug: LX4211, Januvia® | Type 2 Diabetes Mellitus | 18 | Nov 2011actual | 2012-01-31 |
| An Open-Label Study of Two Formulations of LX1033 in Healthy Human SubjectsNCT01411800Urinary 5-HIAA levelsRandomized · Open-label · Treatment | Phase 1 | Completed | Drug: 250 mg capsule, 250 mg tablets | Irritable Bowel Syndrome | 28 | Oct 2011actual | 2012-07-20 |
| A Study to Determine the Pharmacodynamics of LX4211 Relative to Meals in Healthy SubjectsNCT01334242Urinary glucose excretionRandomized · Quadruple-masked · Treatment | Phase 1 | Completed | Drug: Schedule A, Schedule B, Schedule C, Schedule D, Schedule E | Healthy | 14 | Apr 2011actual | 2011-05-19 |
| A Study to Evaluate the Interaction of LX4211 and Metformin in Healthy SubjectsNCT01292993Plasma concentration of LX4211 and metformin after concurrent single-dose administrationRandomized · Open-label · Treatment | Phase 1 | Completed | Drug: 400 mg LX4211, 1000 mg metformin | Type 2 Diabetes Mellitus | 18 | Mar 2011actual | 2011-03-30 |
| Study of Two Oral Formulations of LX4211 in Patients With Type 2 Diabetes MellitusNCT01188863Maximum observed plasma concentrationRandomized · Open-label · Treatment | Phase 1 | Completed | Drug: 300 mg LX4211 (150 mg tablets), 300 mg LX4211 (50 mg tablets), 300 mg LX4211 (liquid) | Type 2 Diabetes Mellitus | 15 | Oct 2010actual | 2011-03-30 |
| Study of LX3305 in Subjects With Active Rheumatoid Arthritis on Stable MethotrexateNCT00903383results2011-12-15ACR20 Response at Week 12Randomized · Quadruple-masked · Treatment | Phase 2 | Completed | Drug: LX3305 low dose, LX3305 mid dose, LX3305 high dose, Placebo | Rheumatoid Arthritis | 208 | Sep 2010actual | 2011-12-15 |
| Study of LX4211 in Subjects With Type 2 Diabetes MellitusNCT00962065results2011-03-03Change From Baseline at Day 28 in 24-hour Urinary Glucose ExcretionRandomized · Triple-masked · Treatment | Phase 2 | Completed | Drug: LX4211 Low Dose, LX4211 High Dose, Placebo | Type 2 Diabetes Mellitus | 36 | Dec 2009actual | 2011-03-03 |
| Study of LX1031 in Subjects With Non-Constipating Irritable Bowel SyndromeNCT00813098results2010-12-02Subjects Who Experienced Relief of IBS Pain and Discomfort at Week 4Randomized · Triple-masked · Treatment | Phase 2 | Completed | Drug: LX1031 High Dose, LX1031 Low Dose, Placebo | Irritable Bowel Syndrome | 155 | Jul 2009actual | 2010-12-02 |
| Study of LX3305 and Methotrexate in Subjects With Stable Rheumatoid ArthritisNCT00847886results2010-06-03Methotrexate Maximum Plasma ConcentrationRandomized · Triple-masked · Treatment | Phase 1 | Completed | Drug: LX3305, LX3305 Placebo, Methotrexate | Rheumatoid Arthritis | 15 | Mar 2009actual | 2010-06-03 |
| Study of LX6171 in Elderly Volunteers With Age Associated Memory ImpairmentNCT00691808results2010-03-03Number of Participants Who Were Exposed to LX6171Randomized · Triple-masked · Treatment | Phase 2 | Completed | Drug: LX6171 High Dose, LX6171 Low Dose, Placebo | Age-Related Memory Disorders | 103 | Oct 2008actual | 2010-03-03 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19